Consistent with our observation, a recent publication showed that targeting overexpressed glutamine metabolism in sorafenib-resistant HCC through the inhibition of peroxisome proliferator-activated receptor-δ (PPARδ) enabled the overcoming of sorafenib resistance in HCC [55]. The gene discussed is PPARD; the disease is hepatocellular carcinoma.